EUVIMED · CrossrefZeitschrift
Bankers, Markets & Investors
ISSN 2101-9304 · Eksa Editions
Neueste Artikel
U.S. Domestic vs. Eurodollar Issuance of Make-Whole Callable Corporate Bonds
Impact of French State-Guaranteed Loans on Company Financial Statements During the COVID-19 Crisis
How Compensation Committees Shape Performance Share Awards to Executives: Insights from Agency and Managerial Power Theories
Does it pay to go green? The impact of green bond issuance on corporate performance
Notes
How institutional framework shapes bank efficiency in Sub-Saharan Africa
Why Do Banks Hold Cash?
Pricing of Internet Companies: Financial and Non-financial Value Drivers
Scrutinizing Portfolio Strategies and Asset Pricing Models: The French Case
Long Term Savings Performances: The 40 Year Track Record of Afer Funds
Spillover Effects of stock markets volatility, and Financial Contagion: Evidence from European sovereign debt crisis
The determinants of the foreign currency hedging strategies
An Examination of the Impact of the EU Ban on Naked Purchases of Sovereign Credit Default Swaps
The myth of CAC 40 high volatility in the 2010s
Real Estate Investing: Opportunities and Challenges
Unlisted Infrastructure: Biases in Appraisal- Based Valuations?
The Value of Private Equity for Institutional Investors
Diversification at a Reasonable Price: Revisiting Alternative Diversification from an Institutional Investor’s Perspective
The cross-border strategies of European banks: Effects on performance
CSR Performance, Dividend Payout and Governance Mechanisms
Bank Acquisitiveness and Bailouts: Evidence on European Banks during the 2008 Financial Crisis
Financial Sanctions in France – 2004-2016
The cross-border strategies of European banks: Effects on performance 2004–12
CSR Performance, Dividend Payout and Governance Mechanisms
Residential Real Estate in a Mixed-Asset Portfolio
Life Insurance with Guarantees
Does Sustainability Reduce Country Default Risk?
Financing Start-ups: the Complementarity of Crowdfunding and Banking
How do CoCo bonds impact a bank’s shareholder wealth?
Basel III Credit Valuation Adjustment Capital Charge and Wrong Way Risk
EUVIMED